The benefits of genetic counselling for DMD

Genetic counselling for DMD offers many benefits for families diagnosed and living with DMD.1–3

Five reasons to refer DMD families to a genetic counsellor:1–3

  1. They provide education about DMD and its therapeutic options
  2. They can coordinate diagnostic genetic testing
  3. They can establish who is at risk of being a carrier and organise carrier genetic testing
  4. They can discuss family planning options
  5. They provide emotional counselling

Expert insights

Want to find out more about obtaining an accurate DMD diagnosis?

Learn more from our DMD experts

Carrier screening for DMD

Family members of an individual with DMD should receive genetic counselling to establish who is at risk of being a carrier.4

Carrier genetic testing should be performed in female relatives of a boy or man who has been genetically confirmed to have DMD.4

Early detection means that women who are carrying the DMD gene mutation can:

  • Be offered genetic counselling, which can inform them about the risks of transmitting the mutated allele in future pregnancies5
  • Have the option of prenatal genetic testing4,5
  • Be made aware of alternative reproductive options, such as the use of donor eggs or human assisted reproduction with preimplantation genetic diagnosis5
  • Undergo regular surveillance for cardiomyopathy from early adulthood4,6
  • Receive early cardiac treatment if heart involvement is detected7,8

Download the summary: International care considerations for DMD

Genetic counselling is also recommended in the International Care Considerations for DMD. Download our summary to find out more.

International care considerations for DMD

lock icon
Complete the form to access this content

Already registered? Log in here to access this content

PTC will retain your information for a limited period of time following your registration, according to PTC’s internal guidelines. Providing your personal data and your consent is voluntary; you have the right to withdraw your consent at any time, without giving any reasons. Click here to view our Privacy Statement.

For any enquiry relating to the processing of your personal data or if you want to exercise your privacy related rights or withdraw your consent, you can contact PTC’s Privacy Office at: Dataprivacy@ptcbio.com.

Thank you!

Your details have been submitted successfully. Click 'download' button to access the document

Download

An early and accurate diagnosis ensures patients receive early access to treatment. Find out more about DMD treatment.

Learn More
A photo of Dr Christian Werner

The content on this page has been reviewed by Dr Christian Werner, Executive Director, Global Medical Affairs

Global Duchenne Muscular Dystrophy Lead, PTC Therapeutics.

This page has been through comprehensive review for informational and educational purposes. Find out more about our content review process.

References

  1. Helderman-van den Enden AT, et al. Clin Genet. 2011;79:236–242.
  2. Institute of Medicine (US) Committee on Assessing Genetic Risks; Andrews LB, et al. editors. Assessing Genetic Risks: Implications for Health and Social Policy. Washington (DC): National Academies Press (US); 1994. 4, Issues in Genetic Counseling. Available at: https://www.ncbi.nlm.nih.gov/books/NBK236049/ [Accessed October 2022].
  3. Duchenne Connect. Genetic Counseling. Available at: https://www.duchenneconnect.org/genetic-counseling.html [Accessed November 2022].
  4. Birnkrant DJ, et al. Lancet Neurol. 2018;17:251–267.
  5. Bianco B, et al. Einstein (Sao Paulo). 2017;15:489–491.
  6. Birnkrant DJ, et al. Lancet Neurol. 2018;17:347–361.
  7. Mavrogeni S, et al. World J Cardiol. 2015;7:410–414.
  8. Adachi K, et al. J Neurol Sci. 2018;386:74–80.
  9. Aartsma-Rus A et al. J Med Genet. 2016;53:145–51.
  10. van Ruiten HJ, et al. Arch Dis Child. 2014;99:1074–1077.
  11. Lurio JG, et al. Am Fam Physician. 2015;91:38–44.

© 2022 PTC Therapeutics.
GL-DMD-0712 | October 2023